PRAX (Praxis Precision Medicines) Tariff Resilience Score: 6/10 (As of Jul. 03, 2026)


PRAX Praxis Precision Medicines Inc PRAX
38 GF Score
Price $319.07
GF Value $27.70
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Praxis Precision Medicines Tariff Resilience Score?

Praxis Precision Medicines PRAX -0.29% 38 Tariff Resilience Score is 6 as of Jul. 03, 2026. GuruFocus rates PRAX with a GF Score™ of 38/100 and a GF Value™ of $27.70 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,373 Biotechnology companies, Praxis Precision Medicines ranks better than 75.97% on this metric.

Praxis Precision Medicines has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Praxis Precision Medicines has Biopharmaceutical company with potential exposure to tariffs on imported raw materials. Global supply chain could be affected, but mitigation strategies include alternative suppliers. Industry-specific exemptions may apply.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Praxis Precision Medicines might have Average Resilient.

Praxis Precision Medicines  (NAS:PRAX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Praxis Precision Medicines Tariff Resilience Score Related Terms

PRAX vs IBRX, CORT, KYMR: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Praxis Precision Medicines's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Praxis Precision Medicines Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Praxis Precision Medicines's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Praxis Precision Medicines's Tariff Resilience Score falls into.


PRAX
38GF Score
Praxis Precision Medicines Inc PRAX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Praxis Precision Medicines (PRAX) has a Tariff Resilience Score of 6 as of Jul. 03, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Praxis Precision Medicines ranks #330 out of 1373 companies in the Biotechnology industry, placing it in the top 24%.
Is Praxis Precision Medicines' Tariff Resilience Score too high?
Praxis Precision Medicines' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Praxis Precision Medicines' value of 6 is 50% above this industry median. Based on the distribution chart, Praxis Precision Medicines ranks #330 out of 1373 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Praxis Precision Medicines has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Praxis Precision Medicines' Tariff Resilience Score compare to IBRX and CORT?
According to the Biotechnology industry distribution chart, Praxis Precision Medicines ranks #330 out of 1373 companies for Tariff Resilience Score. This places Praxis Precision Medicines in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Praxis Precision Medicines' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Praxis Precision Medicines's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Praxis Precision Medicines's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Praxis Precision Medicines stock overvalued right now?
Based on GuruFocus' analysis, Praxis Precision Medicines (PRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $27.70, compared to a current price of $319.07 — trading 1051.9% above its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Praxis Precision Medicines' overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Praxis Precision Medicines (PRAX), the current Tariff Resilience Score is 6 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Praxis Precision Medicines (PRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Praxis Precision Medicines stock appears to be overvalued. The current stock price of $319.07 is trading 1051.9% above its estimated GF Value™ of $27.70. GuruFocus considers Praxis Precision Medicines to be Significantly Overvalued.

Key valuation signals for PRAX:

  • Tariff Resilience Score: 6
  • GF Value™: $27.70 vs. price of $319.07 (1051.9% above fair value)
  • GF Score™: 38/100 with 3 warning signs
  • Industry Position: 50% above the Biotechnology median (#330 of 1373)

No single metric tells the full story. See the PRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Praxis Precision Medicines Business Description

Address 99 High Street, 30th Floor, Boston, MA, USA, 02110
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
38GF Score

Get the complete analysis for PRAX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$319.07
Price
$27.70
GF Value